SCHEMBL3287480

SCHEMBL3287480

[CH2]CNCCNCc1ccoc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 2/20 0.40
HPGD P15428 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
CTDSP1 Q9GZU7 1/20 0.33
TSHR P16473 1/20 0.33
ALOX5 P09917 1/20 0.33
CLK4 Q9HAZ1 1/20 0.32
FAAH O00519 2/20 0.31
MAOA P21397 1/20 0.31
PDE10A Q9Y233 1/20 0.31
FYN P06241 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
CNR2 P34972 1/20 0.31
RECQL P46063 1/20 0.31
BLM P54132 1/20 0.31
SLC1A3 P43003 1/20 0.31
SLC1A2 P43004 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13102160 0.78 MCHR1 (0.41) MCHR1HPGDMEN1KMT2ATDP1
SCHEMBL8350573 0.78 MC4R (0.44) MCHR1HPGDMEN1KMT2ATDP1
SCHEMBL2717162 0.74
SCHEMBL13123466 0.74
SCHEMBL8438966 0.73 HPGD (0.39) MCHR1HPGDMEN1KMT2ATDP1
SCHEMBL1628917 0.73
SCHEMBL6421867 0.72 MEN1 (0.52) HPGDMEN1KMT2ATDP1TSHR
SCHEMBL5069114 0.72 CA1 (0.51) MAPT
SCHEMBL8436149 0.70 GAA (0.63) MEN1KMT2ATDP1MAOAALDH1A1
SCHEMBL19145053 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2258708-A1 Macrolide compounds endowed with antiinflammatory activity Zambon S.p.A. (IT) 2010-12-08 EP disclosed
US-7704960-B2 Macrolide compounds endowed with antiinflammatory activity ZAMBON GROUP S.P.A. (IT) 2010-04-27 US disclosed
US-20090054357-A1 MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY ZAMBON GROUP S.P.A. (IT) 2009-02-26 US disclosed
US-7488811-B2 Macrolide compounds endowed with antiinflammatory activity ZAMBON GROUP S.P.A. (IT) 2009-02-10 US disclosed
US-20060058246-A1 Macrolide compounds endowed with antiinflammatory activity ZAMBON GROUP S.P.A. (IT) 2006-03-16 US disclosed
EP-1529053-A2 MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY ZAMBON GROUP S.p.A. (IT) 2005-05-11 EP disclosed
WO-2004013153-A2 MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY ZAMBON GROUP S.P.A. (IT) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054357-A1 MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY CEL, MPO, IL6 MCHR1 1781/4885HPGD 2752/4885MEN1 4049/4885
US-20060058246-A1 Macrolide compounds endowed with antiinflammatory activity CEL, MPO, IL6 MCHR1 1781/4885HPGD 2752/4885MEN1 4049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.